Home > Journals > Acta Vulnologica > Past Issues > Acta Vulnologica 2014 December;12(4) > Acta Vulnologica 2014 December;12(4):187-92





A Journal on Physiopathology and Therapy of Chronic Cutaneous Ulcers

Official Journal of the Italian Association for Cutaneous Ulcers
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index




Acta Vulnologica 2014 December;12(4):187-92

language: English, Italian

A novel methacrylate powder dressing (Altrazeal®) for hard-to-heal wounds. Case report

Fraccalvieri M., Morozzo U., Salomone M., Ruka E., Fava R.

Department of Plastic, Reconstuctive and Esthetic Surgery, University of Turin, Turin, Italy


Chronic wounds have a major impact on the quality of life of patients and place a significant economic burden on healthcare systems. Optimal therapeutic strategy for clinical resolution of chronic wounds relies on promoting healing and tissue re-epithelialization, while ensuring protection against external bacterial infections which can delay healing and pose a life-threatening health risk. A novel methacrylate powder dressing (Altrazeal®, Uluru Inc, Addison, TX, USA) has shown promising clinical results in the treatment of skin ulcers by virtue of its ability to form a protective barrier film and serve as a drug delivery vehicle for antiseptics, thus considerably reducing the bacterial load. The product consists of a sterile white powder in a single use, sterile foil-laminate pouch. When hydrated by wound exudate or sterile saline, the aggregated powder particles form an intimate contact with the surface of the wound bed. We obtained good clinical results, with complete wound closure in a patient with a chronic leg ulcer that had been unsuccessfully managed with multiple treatments.

top of page

Publication History

Cite this article as

Corresponding author e-mail